 |
| (사진= 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Dongwon Group, famous for tuna cans and Dongwon tuna, is reaching out to the bio-industry that develops vaccines and new drugs.
Dongwon Industrial, a holding company of Dongwon Group, announced on the 23rd that it was selected as the preferred bidder for the sale of Boryeong Biopharma management rights of Boryung Group and signed a memorandum of understanding with Boryeong Partners.
Boryung Partners is the largest shareholder with a 62.29% stake in Biopharma and plans to sell a 100% stake in Boryung Biopharma, including the stake of CEO Kim Jung-kyun, the third-generation owner of Boryeong Group.
Earlier, it was confirmed that Boryung Partners and Samil PwC, the organizer of the sale, conducted a preliminary bid last month, omitted to select a 'qualified candidate' (shortlist) and gave Dongwon Industry a chance to conduct due diligence alone.
The sale price mentioned in the market is around 500 billion won. Dongwon Industrial will form a consortium with Korea Investment Private Equity (Korea Investment PE) and Korea Investment Partners to take over.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
